Skip to main content

Radiation oncology researchers from The University of Texas MD Anderson Cancer Center (MD Anderson CC), presented results from a Phase III randomized clinical trial studying the effects of Whole Brain Radiation Therapy (WBRT) on patients’ cognitive function in comparison to radiosurgery. The study results, which suggested that the negative impact on cognitive function outweighs any benefit associated with WBRT and tumor control, were presented during the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Brain CancerConnect 490

Metastatic brain cancer, which is also called secondary brain cancer, occurs when cancer cells spread to the brain from a primary cancer elsewhere in the body, forming a tumor or tumors in the brain. Each year close to 200,000 people in the United States are diagnosed with brain metastases. WBRT is a commonly utilized therapy after surgery or radiation to treat this type of cancer.

Previous studies have shown that WBRT is associated with a significant improvement in tumor control, but the measure of cognitive decline that is associated with this treatment modality has not been tested.

In a University press release about the study, Dr. Paul Brown, MD., professor, Radiation Oncology, and corresponding study author, explained “The question we were left with, was understanding the toxicities associated with whole brain radiation therapy, specifically cognitive function. We needed to understand what’s worse – the cognitive impact of the whole brain radiation therapy, or, in other words, the therapy itself, or the recurrence of tumors.”

To measure cognitive impact researchers randomized 213 patients from 2002-2013, all with one-to-three brain metastases, into two different treatment groups:

Scroll to Continue

Recommended Articles

Image placeholder title

Kisqali Improves Survival in Premenopausal ER+ Advanced Breast Cancer

Kisqali prolongs survival for Pre-menopausal ER positive HER2 Neg breast cancer. San Antonio 2020 update.

Melanoma

Treatment of Stage III Melanoma

Genomic testing should be performed in all patients-precision medicines reduce recurrences and prolong survival.

Non Small Cell Lung Cancer News Updates NSCLC

Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patient

Immune-Targeting Drug Combo Shows Promise for Non-Small Cell Lung Cancer Patients, Say Moffitt Cancer Center Researchers

  • radiosurgery alone
  • radiosurgery followed by WBRT

Patients’ cognitive decline was then measured at the 3 month mark using a series of 7 cognitive functioning tests, and compared by treatment received.

The primary study findings showed that cognitive decline was more frequent in the WBRT-radiosurgery treatment group when compared to those who received radiosurgery alone. Other important findings included:

  • Greater loss of immediate recall was observed in the WBRT-radiosurgery treatment group
  • Greater loss of delayed recall was observed in the WBRT-radiosurgery treatment group
  • Greater loss of verbal fluency was observed in the WBRT-radiosurgery treatment group
  • Tumor control was higher in the WBRT-radiosurgery treatment group
  • There were no differences observed in the survival rates between the two treatment groups
  • Patients treated with WBRT and radiosurgery had a worse quality of life when compared to those treated with radiosurgery alone.
Brain Cancer Newsletter 490

In a statement about the impact of the study’s findings, Dr. Brown, said, “Our study gives us the clearest picture of the impact of WBRT on cognitive function. To date, we’ve really not had that. Overtime there’s been a general shift in moving away from using whole brain radiation, in favor of stereotactic radiosurgery. With these results and appropriate concerns for cognitive decline, it will likely be pushed even further, reserving WBRT for later in a patient’s disease course.”